The company has developed a drug delivery technology that uses an artificial intelligence-driven health span diagnostic system, a needleless medication delivery medical device, and a preventive healthcare center to treat age-related diseases. This patent-pending technology, called Telosis, helps patients deliver medications subcutaneously or intramuscularly without a needle and manage their chronic condition and medication adherence on the patient engagement APP. NovaXS Biotech aims to optimize patients’ medication self-administration experience and improve treatment outcomes while helping pharmaceutical partners reduce their COG by 30%, increase revenue with improved patient compliance, and boost the efficacy of medication with a better absorption rate. The company is led by a professional team in healthcare with a proven track record of over 40 million fundraising experience and 5 successful business exits, and its current partners and investors include Baxter, Edward-Elmhurst Health, Helixmith, etc.